- Home
- IRON vs NYAX Comparison
IRON vs NYAX Comparison
Compare IRON & NYAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- NYAX
- Stock Information
- Founded
- IRON 2017
- NYAX 2005
- Country
- IRON United States
- NYAX Israel
- Employees
- IRON N/A
- NYAX N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- NYAX
- Sector
- IRON Health Care
- NYAX
- Exchange
- IRON Nasdaq
- NYAX Nasdaq
- Market Cap
- IRON 2.1B
- NYAX 1.8B
- IPO Year
- IRON N/A
- NYAX N/A
- Fundamental
- Price
- IRON $85.63
- NYAX $44.34
- Analyst Decision
- IRON Strong Buy
- NYAX Buy
- Analyst Count
- IRON 13
- NYAX 5
- Target Price
- IRON $102.23
- NYAX $46.67
- AVG Volume (30 Days)
- IRON 623.6K
- NYAX 7.9K
- Earning Date
- IRON 11-11-2025
- NYAX 11-11-2025
- Dividend Yield
- IRON N/A
- NYAX N/A
- EPS Growth
- IRON N/A
- NYAX N/A
- EPS
- IRON N/A
- NYAX 0.57
- Revenue
- IRON N/A
- NYAX $348,663,000.00
- Revenue This Year
- IRON N/A
- NYAX $31.84
- Revenue Next Year
- IRON N/A
- NYAX $22.85
- P/E Ratio
- IRON N/A
- NYAX $76.57
- Revenue Growth
- IRON N/A
- NYAX 29.63
- 52 Week Low
- IRON $30.82
- NYAX $25.32
- 52 Week High
- IRON $95.95
- NYAX $52.46
- Technical
- Relative Strength Index (RSI)
- IRON 69.02
- NYAX 34.82
- Support Level
- IRON $83.52
- NYAX $43.73
- Resistance Level
- IRON $89.00
- NYAX $46.12
- Average True Range (ATR)
- IRON 3.84
- NYAX 0.76
- MACD
- IRON 1.08
- NYAX -0.45
- Stochastic Oscillator
- IRON 64.05
- NYAX 10.90
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About NYAX Nayax Ltd.
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It provides consumers with digital, cashless payments, and connected commerce experiences, enhancing consumer conversion and loyalty. Its platform addresses the entire unattended commerce value chain, including a payments infrastructure, a commerce software suite, a consumer engagement platform, and integrated POS devices. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.